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VOLUME XLIII APRIL 1969 NUMBER 4
PHYSICIAN'S LIABILITY FOR PRESCRIPTION
DRUGS
ALBnRT AVERBACH
INTRODUCTION
T mi Registry of Tissue Reactions to Drugs located
at the Armed Forces Institute of Pathology, Wash-
ington, D.C., reports findings that one in twenty beds
in a general hospital is occupied by a patient suffering
from a complication of chemotherapy, and that one in
seven patients will suffer some kind of a drug reaction
during hospitalization.'
In a three month period at Johns Hopkins Hospital,
122 of 714 general medical service patients (17.1%) had
an adverse reaction to medication.2 In the same period,
97 patients (13.6%) acquired an adverse reaction during
hospitalization. Of 36 patients admitted because of a
drug reaction, 11 (30.4%) acquired another reaction in
the hospital. Eight of the 36 patients died, five from
the reaction for which they were admitted to the hospital
and three of a reaction acquired in the hospital.
In the year beginning July, 1965, all patients ad-
mitted to a public medical service of the Montreal General
* LL.B., Albany Law School; Former President International Academy
of Trial Lawyers; Honorary Fellow of the American College of Legal
Medicine; Member of the New York Bar.
1Cluff, et. al., Studies on the Epidemiology of Adverse Drug Reactions,
188 J.A.M.A. 976 (1964), reports the same ratio in a four week study of
admittances due to adverse responses to drugs.
2 CL N-ALERT Nos. 2, 142 (1967).
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Hospital were surveyed for drug reactions occurring during
hospitalization.3 Of 731 patients, 132 (18%) experienced
193 reactions, the majority of which were severe enough
to require specific corrective therapy, prolonged hospital-
ization or which were life threatening or fatal. One-
quarter of the 67 deaths on the service were the result of
adverse drug reaction. In addition to the above, 48 pa-
tients were admitted because of drug reactions outside
the hospital and of these, 15 had further reactions in
the hospital."
These statistics are from hospital services alone in
special studies designed to measure the incidence of drug
reactions. No such measurement has been attempted in
the case of the general populace, but it is reasonable
to suppose that presently, and in the years ahead, hundreds
of thousands of people will be injured or killed through
the media of supposed life preserving medications. Anaphy-
lactic reactions to penicillin alone are said to occur in
one to five out of every 1,000 patients and it has been
estimated that there are about 90,000 such anaphylactic
reactions annually.5 The figure is deemed conservative
because of the incidence of unreported cases.
The problem of gathering statistics is further com-
plicated by the fact that a drug reaction may mimic a
serious disease and thus go unrecognized. Also, drugs
are often given in concert with other drugs so that it
may be impossible to pinpoint the cause of an untoward
result.
In the years 1952-1961 alone, 4,562 new drug products
were marketed in the United States.' New pills (not all
397 CAN. M.A.J. 1458 (1967); CLIN-ALmT No. 1 (19M8).
4 There is a similar report from the University of Western Ontario of
104 persons who at some time during a 59 day period occupied a 31 bed
medical ward. In all, 23 errors in drug administration in 20 patients were
noted and 30% of the 104 patients had adverse drug reactions or were
subject to error in the administration of drugs. See CuwN-AI aT No. 273(1967). A follow-up study of the same Montreal investigators produced a
slightly better result. See 98 CAN. M.A.J. 175 (1968); CLiN-A=.a'r No. 51
(1968).
5 Shafer, Penicillin Reactions, 3 L. MED. J. 387 (1968).6 DeHaen, New Products Parade 1961, 90 CosmETic & DRUG INDUSTRY
142 (1962).
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miracle drugs) have been flooding the market at the rate
of one a day. To compound matters further, 90% of
the prescription drugs now in use did not even exist
20 years ago. Most of the antibiotics, steroids, antihis-
tamines and tranquilizers have been developed and put
on the market since the average-aged doctor left medical
school.
Although the rule of law is that a physician must
keep abreast of the times and follow approved methods
in general use, the current crop of chemical creations has
threatened to nullify his skills by antiquating his education
and training by adding new lore at a rate he cannot hope
to absorb while practicing his profession. The doctor
cannot ignore the host of new drugs, but to keep up with
published reports of them is out of the question.7
It is patent that the role of the doctor in the purveying
of drug products is of prime importance, since he is the
vehicle by which the medication is transferred from the
manufacturer to the consumer. The vice is that since
the doctor cannot hope to ferret out all vital information
concerning drugs for himself, he is usually consigned to
obtaining his knowledge from the manufacturer. It is a
fact that most information concerning drug products which
comes to the attention of the average physician is heralded
by the detail men of the drug companies whose design
is to push their products, or from drug company advertis-
ing in one form or another. And this is where the
problems of the doctor begin.
The human being is an extremely complicated dynamic
system and there is considerable variation in the system
from one person to another. As to any particular drug,
the dosage form was once thought of as a pharmaceutical
carrier used to deliver the labeled amount of active in-
gredient to the patient. Today, because of increased
biological knowledge, the problem of the drug formulator
is much more extended. He must be concerned with the
7The National Library of Medicine has estimated that about 200,000
articles on drugs are published each year.
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absorption, distribution, metabolism and excretion of the
drug in an intact biological system-a live human being.'
Thus, a particular drug dosage should be thought of as a
physical system which is entrusted with the task of de-
livering the drug to the site of its absorption in the most
efficient, predictable and reproducible manner2
As to the individual physician, his problem is that
he knows of the medication only what the manufacturer
has seen fit to tell him. Thus, when a new drug comes
on the market, the dispensation of it is to use the patient
as a guinea pig in the testing process. The physician
cannot know of the long range effect of the therapy,"0
nor of the results possible when drugs are used in -com-
bination. For example, an astonishing number of drugs
modify the response to certain types of anticoagulants. 11
Barbiturates decrease the anticoagulant result." To main-
tain a therapeutic effect, larger doses of anticoagulant are
required when barbiturates are administered at the same
time. Further, many patients receiving the dual admin-
istration are erratic in their response to it. Moreover,
if it is decided to withdraw the barbiturate, which may
take several weeks to accomplish, increasingly smaller
doses of the anticoagulant are required. If there is not
constant laboratory testing and supervision, overdosage
and hemorrhaging may be the result. A drug house
formulator cannot advise physicians in such particular
cases.
In addition, countless physicians are induced to prac-
tice out of their field by glowing promises of results to
be attained as set forth in drug advertisements in medical
8 See Tingstad, The Use of Biological Data in the Design of Phar-
maceutical Dosage Forms, 5 LEx Er SCMNTIA 105 (1968).
9Id.
10 For example, that Chloroquine (Aralen) induced occular damage is
apparently related to the amount of the drug taken rather than the daily
dose. The drug is stored in the melanin-bearing tissues of the eye where
it remains long after it has been eliminated from the other parts of the
body. Even small doses exert a cumulative effect. See Leading Articles,
1 BRnsH ME. J. 254 (1967).
"'See CrsN-AsixT No. 103 (1968).
"2MacDonald & Robinson, Clinical Observations of Possible Barbituate
Interference With Anti-Coagulation, 204 J.A.M.A. 97 (1968).
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journals, brochures mailed to the practitioner's office replete
with samples, and by the detail men.
A psychiatrist 1 reviewed 133 referrals sent to him for
evaluation and/or treatment. All patients had been under
the care of non-psychiatrist physicians. Of 93 patients
who had been on some type of drug therapy, 90 were
considered unresponsive. The greatest source of drug
failure was inappropriate prescribing. There were 42
cases in which drugs were misused and nearly as many
patients had chronic illnesses which could not reasonably
have expected to improve with medication. In addition
to the 42 cases, there were 30 in which nonpsychothera-
peutic drugs were used for emotional disorders. In many
instances drugs were given without objective evidence of
an organic condition to justify their use, e.g., thyroid
for euthyroid patients, anti-convulsants for patients with-
out seizures, hormones for women without menopausal
symptoms, iron for patients without anemia, etc. The
schizophrenics received inadequate or no treatment. Of
these, 8 had been to their family doctor without psychiatric
care or referral, 19 had received inappropriate psycho-
pharmacologic drugs and 7 received nonpsychopharmacologic
drugs."'
It is an understatement to allege that our present
day society is drug conscious. We are exposed to drugs
not only for the treatment of disease entities, but for
manifold other purposes. They are used for anesthesia
as well as analgesia, to put us to sleep, to wake us up,
to tranquilize the over-anxious, to stimulate the depressed,
as well as for the diagnosis of specific ailments. Drugs
have been developed which modify one's personality by
expanding memory functions and which change life cycles
by affecting menstrual and menopausal functions.
There is a growing recognition that all drug usage
involves some risk. 5  Drug induced injury is the price
paid by society for development of drug technology. What
123 Lynn, 57 IND. M.A.J. 1229 (1964).
'4See CLIN-ALEIer No. 357 (1964).
'2 See Modell, Hazards of New Drugs, 139 SCIENCE 1180 (1963).
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is more important is that the public is becoming drug
reaction conscious. It is becoming increasingly clear that
people at large will continue to support new drug develop-
ment only to the extent that the law provides appropriate
and adequate remedies for those injured and killed by
drug products. The victim is clearly entitled to com-
pensation from those responsible, the doctor, the drug com-
pany, the pharmacist, the hospital or the nurse, if the
injury could have been avoided in the exercise of reasonable
care.
In recent years there have been many verdicts in
drug reaction cases totaling millions of dollars.6 Similar
awards and settlements in startling amounts have been
reported in cases involving chloromycetin, polio vaccine,
MER/29, measles vaccine, and many others. Awards have
been made for neurotoxicity related to penicillin, renal
damage caused by methicillin, deafness related to neomycin
and kanamycin, and vestibular dysfunction caused by strep-
tomycin.
Thirty years ago drugs were used almost indiscrim-
inately, but then it was of lesser consequence, for fewer
drugs were available for prescription, and, of those that
were, most were inconsequential so that if the patient was
not benefited by the prescription, at least he was not
hurt.1" In those days, the physician did not see the
16 In Stromsodt v. Parke, Davis & Co., 257 F. Supp. 991 (N.D.N.D.
1966), an award of $651,783 was made in the case of an 8 year old boy
who at the age of 3 months was immunized with Quadrigen, a quadruple
vaccine. He was left with irreversible brain damage, mental retardation
and right-sided paralysis. In Morgan v. Sterling Drug, Inc., an award of
$550,000 was made to a 38 year old woman who became blind as the result
of the administration of Aralen for rheumatoid arthritis. In Kershaw v.
Sterling Drug, Inc., a companion case, a plaintiff was awarded $150,000.
11 A.T.L. ASS'N NFwsLarrm 152 (May 1968). Other awards in reported
Aralen cases are: Sterling Drug, Inc. v. Cornish, 370 F.2d 82 (8th Cir.
1967) ($80,000) ; Yarrow v. Sterling Drug, Inc., 263 F. Supp. 159 (S.D.S.D.
1967) ($180,000); Bine v. Sterling Drug, Inc., 422 S.W.2d 603 (Mo. 1968)
($175,000 reduced on remittitur to $125,000); Krug v. Sterling Drug, Inc.,
416 S.W.2d 143 (Mo. 1967) ($125,000).
17 The role of the pharmacist today has been reduced from the careful
compounding of prescribed elixers to interpretation of the doctor's hand-
writing, counting the requisite number of pills, and typing the 4irections for
use.
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necessity of informing his patient of the medication he
was administering. When a new drug came on the
market, e.g., penicillin, it was considered a panacea and
was prescribed for all ailments, even when the supply of
it was scarce, in amounts which by modern standards
would be considered inadequate, because not enough was
known of it.
Literature on drug toxicity did not begin to accum-
ulate until the late 1930's with the advent of the sulfon-
imides which greatly enlarged the scope of chemotherapy.
The greatly increased availability of antibiotics in the
'40's and '50's gave greater rein to physicians generally in
their combat against disease, but actual knowledge of ther-
apeutic misadventure was largely confined to medical
journals and the medical profession. The great mis-
adventure which alerted the general public to drug tox-
icities, allergies and idiosyncracies was the thalidomide
disaster which produced grotesque birth defects in the
early 1960's. Even now they are the subject of much
comment and concern in the fields of sociology, psychology
and economics as well as medicine.
DRUG Toxiclry
Every physician knows that the use of a drug involves
at least a remote possibility of an unfavorable response
to it. Not only may a patient's intrinsic hypersensitivity
cause a reaction, but there is a possibility that the amount
of the dosage, the mode of administration and even the
speed of the injection may cause an unfortunate reaction.
It may be that a great percentage of such reactions are
unpredictable, but there are occasions where a physician,
in proper medical practice, can prophesize the possibilities
of a reaction with a great degree of probability.
On the other hand, the pharmacologist regards all
dosages as toxic and he views the undesirable effect of
a drug merely as one which is not beneficial. The pharma-
cologist knows that all dosages achieve their effect by
the disturbance of one organ system in preference to an-
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other. 8  According to the Food and Drug Administration
definition, an adverse drug reaction is one that is noxious,
unintended, and occurs at doses normally used in man for
the prophylaxis, diagnosis or therapy of disease, or for
the modification of physiological functions. More simply
put, it is a reaction to a drug in a patient which was not
intended. The results of the administration of a drug
which are severe enough to be called side effects or toxic
reactions are always present to some degree although
they may be so minor as not to be noticed by a person
taking them. But it matters little to the pharmacologist
whether the incidence of reaction is high or low, for he is
aware that there is a dosage in which, in a given situation,
any drug will produce toxicity.
"Idiosyncracy" is a word used more by the courts than
by those in the field and it is largely employed as a waste
basket term to describe an allergic or toxic reaction. It
implies that there is some built-in mechanism in a person
which causes him to respond abnormally to a medication.
There are some cases which fall into this category, but
the pharmacologist avoids the use of the word since it
has implications which he would describe otherwise.19
The pharmacologist places drug toxicities into three
general catagories:
1. Where the reaction is minor. As indicated, there
is always some complication to drug administration, even
if so minor as not to be readily noticed. If there is a
noticeable response to the drug, it usually takes the form
of a headache, nausea, fatigue or of just not feeling well.
Unless the symptoms are severe, the physician usually
disregards the complaint on the theory that the patient
will be more benefitted by the drug than the slight discom-
fort he might have to endure. Such minor toxicities are
not often the subject of lawsuits except under unusual
18 See DiPalma, Recognizing Drug Injuries, in DRUG LIAumY LrrrGA-
TION 1 (Unv. of Mich. Handbook No. 22, 1967).
19 Id.
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circumstances. One such circumstance which has given
rise to litigation is in the prescription of antihistamines
without appropriate warnings that the user might become
drowsy.2
2. Where the reaction is reversible in most instances.
The examples are skin rashes, fever and the like. The
symptoms disappear on withdrawal of the drug without
permanent injury. Unless there is some harmful residual,
this type of reaction does not usually give rise to litigation.
It should be noted, however, that drug reactions some-
times do not commence promptly following the institution
of drug therapy. Correspondingly, they sometimes do not
stop immediately after administration of the medication is
halted. It is not like turning a light on and off.
3. Where the reaction is irreversible. This type of
situation is always a potential embryonic lawsuit. The
examples are: teeth staining in the case of tetracyclines;
cataracts in the case of MER/29; visual impairment in
the case of Chloroquine (Aralen) ; aplastic anemia in the
case of sulfonimides; and many others.
CONSIDERATIONS BASIC To SuIT
Cases of allergic toxicity are always difficult to pre-
pare and prove. Unless the patient has suffered a sub-
stantial, irreversible injury, it is usually better to forego
the claim than to take on the case. The usual intangibles
which plague the plaintiff's attorney are whether the pos-
sibility of a reaction could have been determined before
the drug was prescribed, whether the reaction was due
to a condition inherent in the person for which no one
could be blamed (the true "idiosyncracy"), or whether the
medication, once started, could or should have been stopped
in time to avoid the undesirable consequence."
2 0 Kaiser v. Suburban Transp. Sys., 65 Wash. 2d 477, 398 P.2d 14
(1965); Whitfield v. Daniel Constr. Co., 226 S.C. 37, 83 S.E.2d 460 (1954).
21 See Side Effects of Drugs, 21 Am. JUR. PRooF OF FACTS 1 (1968),
particularly the tables beginning at page 70.
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Most drugs, reactions to which are capable of pre-
testing, do not need that prerequisite. Furthermore, such
determinations are frequently uncertain. In all cases how-
ever, it is valid to inquire whether the blame for a drug
reaction was due to the drug, the patient or the physican.
Under ordinary circumstances, assuming that the
drug was wholesome when placed on the market, and
that warnings and contraindications as to its use should
have been known, or were plainly indicated, or readily
available, the inquiry of the attorney should be somewhat
along the following lines:
1. The manufacturer's literature, or PHYSICIAN'S
DESK REFERENCE, should be examined to ascertain
whether the drug was contraindicated in the case, whether
by foresight or hindsight. The literature concerning the
drug should then be carefully researched.22 The concern
is improvement of the attorney's knowledge with a view
to determining the substance of the case. It should be kept
in mind that the package insert is concerned with a drug
and that it is not intended to instruct the physician in
the diagnosis of diseases or in the recognition of patholog-
ical states. It is not intended to replace the doctor's basic
learning as to pharmacology or drug therapy.
2. The next point of inquiry, sometimes the most
fertile one, should be whether the drug prescribed was
medically indicated in the case, or whether the physician
2 2 The following texts may be found useful: BECKMAN, DILEMMAS IN
DRUG THERAPY (1967); BECKMAN, DRUGS, THEIR NATURE & USE (1958);
GOODMAN & GILMAN, THE PHARMACOLOGICAL BASIS OF THERAPEUTICS
(1958).
At intervals, The Medical Clinics of North America publishes a
volume on "Efficacy of New Drugs." The two most recent are the issues
for March, 1964 and September, 1967.
See also Robinson, Antinicrobic Drugs, Their Action, Use and Adverse
Effects, in CANTOR, TRAUMATIC MEDICINE AND SURGERY FOR THE ATTORNEY
141 (Supp. Serv. 1964).
FALCOVER et. al., THE DRUG, THE NURSE, THE PATIENT is basic and
contains the Current Drug Handbook.
Two services to which reference should be made are: CLIN-ALERT,
published by Science Editors, Inc., Morrisville, Ky. and the MEDICAL
LETTER ON DRUGS AND THERAPEUTICS, published by Drug and Therapeutic
Information, New York, N.Y.
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should have, in the exercise of reasonable care, prescribed
a more benign or perhaps longer established drug.23
3. The attorney should then ascertain whether, in
the exercise of due care, the reaction sustained should
have sooner been discovered in the particular patient.
Inquiry should be directed as to whether proper treat-
ment was promptly instituted following the reaction.
Attorneys handling drug claims against physicians
must realize that inevitably the defense will be that
whatever error occurred was the exercise of judg-
ment for which there could be no liability. To support the
defense, there will be available as much expert medical
testimony as may seem to be required.
In a representative case,' it was held that, a trial
court properly directed verdicts in favor of two physicians
and the manufacturer of Dilantin, a drug used to control
convulsive seizures. The physicians, general practitioners,
in consultation with a neurologist, diagnosed the plaintiff's
ailment as a severe type of epilepsy and they prescribed
11/2 grains of the drug three times a day. Within three
weeks the plaintiff developed a high fever and a rash
over much of his body which was diagnosed as measles.
Several weeks later he became feverish and jaundiced. He
had a rash and his spleen and liver were enlarged and
palpable. An allergic reaction to Dilantin was suspected,
but on the basis of symptoms and laboratory tests the
plaintiff's ailment was diagnosed as infectious mono-
nucleosis. He was hospitalized and the drug was dis-
continued to determine whether it was causing any re-
23 The Council on Drugs of the American Medical Association has fre-
quently noted no discernible advantage to a newly marketed medication.
For example, as to six of the newer minor tranquilizers, it stated:
On the basis of the current evidence, the Council can find no general
advantage in the use of these newer agents; thus, the physician should
use discretion when prescribing any of these in place of an older,
well-established drug of similar therapeutic range and safety ratio
with which he may already be thoroughly familiar.
NEW AND NONOFFICIAL DRUGS-AN ANNUAL COmrPILATION OF AVAILABLE
INFORMATION ON DRUGS INCLUDING THEIR THERAPEUTIC, PROPHYLACTIC AND
DIAGNOSTIC STATUS, AS EVALUATED BY THE COUNCIL ON DRUGS OF THE
AmERICAN MEDICAL ASSOCIATION (1963).
24Fritz v. Parke, Davis & Co., 277 Minn. 210, 152 N.W.2d 129 (1967).
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action. A week later the drug was started again at half
the prior dosage and, when the plaintiff was released from
the hospital ten days later, it was discontinued. He was
told to see his physicians periodically for observation
and he returned twice. He died more than a year later
while undergoing surgery.
On the trial of the case, a neurologist testified that it
was highly probable that the Dilantin caused toxic damage
to the plaintiff's liver which was responsible for his
death.
The defendants' evidence was that there are at least
five drugs, including Dilantin, on the market which are
commonly used to control epilepsy and that all five could
produce serious side effects in certain persons; that there
is disagreement among physicians as to which drug is
preferable; and, that the drug does control certain types
of epilepsy and did control the plaintiff's seizures.
The court held that the physicians clearly were not
negligent in the initial prescribing of Dilantin, that a
physician may adopt a mode of treatment approved by a
considerable number of physicians. The evidence was that
the use of Dilantin to control epilepsy was widespread and
that the neurologist's opinion that it was highly probable
that the drug had damaged the plaintiff's liver and con-
tributed to his death was not sufficient to establish that
the doctors were negligent in continuing to use it. The
defendants' expert testimony was that their care and
treatment of their patient was in accord with accepted
standards of practice and thus there was no evidence to
support a finding of negligence.
A further consideration of the plaintiff's attorney in
a proper case is application of the doctrine of informed
consent.2" In its usual sense, this doctrine holds that the
25 Probably the leading and certainly the most quoted from case on
informed consent is Salgo v. Leland Stanford Jr. Univ. Bd. of Trustees,
154 Cal. App. 2d 560, 578, 317 P.2d 170, 181 (1957), wherein it was said:
A physician violates his duty to his patient and subjects himself to
liability if he withholds any facts which are necessary to form the
basis of an intelligent consent by the patient to the proposed treat-
ment. Likewise the physician may not minimize the known dangers
of a procedure or operation in order to induce his patients consent.
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right of a person to control what is to be done to his
body is inviolate, that in medical cases a physican cannot
force his attendance upon his patient no matter how badly
he may conceive him to be in need of treatment. As a
corollary, the rule requires explanation to the patient of
the form of the treatment proposed and what risks may be
involved so that the patient may make an informed choice
as to whether to submit to the treatment.
As applied to medical therapy, it may be the phy-
sician's duty to inform his patient that there may be some
risk or discomfort in connection with the administration
of certain drugs. Oddly enough, the suggested application
of the doctrine came first from pharmacologists and pathol-
ogists. The parallel is that it is now considered necessary
to secure the consent of the patient to even a minor opera-
tion where the risk may be relatively small. Why then should
it be any the less reasonable to exact the requirement of
consent for the administration of a drug where the risk
may be considerably greater than for ordinary surgery?
No clinically useful drug is devoid of toxicity and no
human being should be exposed to needless risk. The neces-
sary inference is that as the risks of drug therapy be-
come more defined, it may be necessary to obtain informed
consents prior to the administration of drugs with po-
tentially dangerous propensities.
THDn PACKAGE "STUFFER"
Essential to an understanding of cases against physi-
cians and drug manufacturers is knowledge of the regula-
tions of the Food and Drug Administration with reference
to package inserts, or "package stuffers," the manufac-
turer's literature packaged with the drug which, among
other things, describes drug dosages and contraindications.
A judicial decision was the touchstone of a controversy
between physicians and the Food and Drug Administration
which still lingers, and which had and will have tremendous
legal repercussions on the liability of doctors in drug cases.
Tn Sanzari v. Rosenfeld,26 a dentist administered lidocaine,
2634 N.J. 128, 167 A.2d 625 (1961).
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an anesthetic, with epinephrine to a patient suffering from
high blood pressure and chronic myocarditis. She suffered
a stroke and thereafter died. The manufacturer's package
insert stated that the use of epinephrine with the anesthetic
was contraindicated in the presence of hypertension. The
plaintiff was unable to obtain the requisite expert testimony
to prove that the dentist was negligent in administering
the drug. The package insert, however, was allowed in
evidence in that warning of a possible side effect was given
and the jury was allowed to find against the defendant on
the ground that the manufacturer's literature stated the
contraindication.
Under the Federal Food, Drug and Cosmetic Act,
and rules and regulations promulgated by the Food and
Drug A&lministration, the basis of drug prescription is the
manufacturer's literature which is placed in the package
which contains the drug.
The Federal Food, Drug and Cosmetic Act of 1938
required the labeling of all drugs, with adequate directions
for use, but made no distinction between over-the-counter
and prescription items." Thereafter, prescription drugs
were exempt from the requirement because it was felt that
physicians, being experts in drug dosage, did not need
labeling directions. A tremendous number of new drugs
came on the market after World War II and the average
practicing physician was then thought not to be able to keep
abreast of the times with respect to drugs through tradi-
tional medical communications media. The fear was that
he would be touted onto drugs by manufacturer's promotion
without always being aware of the dangers of them, and
their side effects and contraindications. 29  Ostensibly to
2721 U.S.C. §351 (1964).
28 Act of June 25, 1938, ch. 675, §§ 501, et seq., 52 Stat. 1049. The law
was tightened after a sulfa drug elixir, distributed without testing by a
small Tennessee manufacturer, was found to have a poisonous ingredient,
not the sulfa, which resulted in the death of nearly 100 persons.
29 In Yarrow v. Sterling Drug, Inc., 263 F. Supp. 159 (S.D.S.D. 1967),
the drug house had satisfied all government regulations in producing and
marketing Aralen, and had used the traditional methods of drug manufac-
turers in providing information and warnings to physicians (descriptive
literature, direct mail and detail men). It was held, on the record made
in the case, that the defendant's detail men did not bring:the side effects
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remedy this situation, in 1961, the FDA promulgated a new
regulation, the essence of which was that an insert be put
on or within prescription drug packages. It required that
[1]abeling on or within the package from which the drug is to
be dispensed bears adequate information for its use, including
indications, effects, dosages, routes, methods, and frequency and
duration of administration, and any relevant hazards, contrain-
dications, side effects and precautions under which practitioners
licensed by law to administer the drug can use the drug safely
and for the purposes for which it is intended, including all
purposes for which it is advertised or presented. . . .3
The Act contemplates proof by the manufacturer that
a drug, before being placed on the market, is safe and effec-
tive for the purpose for which it was intended. This proof is
submitted to the FDA in the form of a New Drug Applica-
tion." It is in effect a report of controlled studies of the
drug conducted by experienced investigators with the train-
ing necessary for them to interpret those studies.'
Following FDA approval of a drug, it comes on the
market with a package insert, or stuffer, usually a single
sheet of paper, in compliance with the labeling regulation.
of the drug to the attention of the plainiff's doctor and that the defendant's
conduct did not constitute a proper warning. Very recently, on appeal, thisjudgment was affirmed by the Eighth Circuit Court of Appeals. See
N.Y.L.J., March 19, 1969, at 1, col. 1.
In Incollingo v. Ewing and Parke, Davis & Co., (Court of Common
Pleas, Philadelphia, Pa., Dec. 1967), a six year old child treated with
Chloromycetin developed aplastic anemia and died. The plaintiff contended
that the defendant pediatrician prescribed Chloromycetin for a minor infec-
tion, that the defendant osteopath authorized refilling of the prescription
without examining the child, and that the manufacturer was guilty of over-
promoting the drug via its detail men whose efforts, in effect, diluted
inadequate printed warnings. The thrust of the complaint was that the
manufacturer, in producing over 72 tons of Chloromycetin knew that
inadequate warnings as to the use of the drug were not being heeded by the
medical profession. The jury brought in a verdict of $215,000 against both
physicians and the drug company. All the manufacturer's labeling, includ-
ing the package insert, brochures and advertising was against the use of
the drug in "trivial" infections, yet the total sales of the drug were
$72,000,000 in 1966.
3021 C.F.R. § 1.106(b) (3) (i) (1968).
31 To illustrate the complexity of gaining new drug approval, a manu-
facturer drew a chart which listed 125 steps to be taken before a drug is
ready for submission.
32 The procedure is outlined in R. GOODMAN & P. REEINOLD, LAWYER'S
DRUG HANDBOOK (1967). See also Rheingold, Products Liability--The
Ethical Drug Manufacturer's Liability, 18 RurrEs L. REv. 947 (1964).
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The content of the stuffer is usually arranged in the follow-
ing order: name of the drug, description, actions, indica-
tions, contraindications, warnings, precautions, adverse
reactions, dosage and administration, and references.
After initial testing and release by the FDA, the re-
ports of the side effects of drugs appear in professional
journals. Although both the FDA and the American Med-
ical Association have set up "early warning" systems so as
to become aware as soon as possible of severe reactions to
newer pharmaceutical agents, the process of compiling seem-
ingly isolated reactions into meaningful trends is painfully
slow."3
As news of adverse reactions to drugs comes to the
FDA, it may require revision of the package insert or even
withdrawal of the drug from the market. Where a major
change is to be made in the precautionary provision of the
insert, the FDA requires this information to be transmitted
to the physician in a distinctively marked envelope. These
have come to be known as "Dear Doctor" letters.
From the viewpoint of the FDA, the burden of proving
the safety and effectiveness of a drug is on the manufac-
turer. Thus, when a new drug comes into the hands of a
physician, the package insert is deemed prima facie proof
that the drug is safe and effective for the uses for which
it is intended. The great issue presented by the package
insert is that when the physician exercises his judgment to
prescribe the drug beyond the limits of the package insert,
it is presumed that he is aware that a scientific basis for
doing so has not been established by information submitted
by the manufacturer through the procedures established by
law. It is at once apparent that an awesome moral respon-
sibility has been placed on the drug houses not to attempt
to market their products for financial gain until there is
assurance that they will do no harm. 4
The difficulties thus presented are the subject of con-
troversy in that the opportunity is presented to the drug
33See Balmer, Manning the Early-Warning Systems for Adverse Reac-
tions to Drugs, 37 MEnicAL REcoD Naws 362 (1966).
,4One of the bases of the MER/29 cases was that the product was
inadequately tested on humans.
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manufacturer to understate effective dosages of its product,
and, in effect, to "disclaim," by flooding the physician with
letters and brochures with "more" information about the
drug, replete with rumors and warnings, and by frequent
visits from detail men. In a collateral sense, the effect is
also to prevent authors from publishing articles based on
experience which do not coincide with the current FDA
approved package stuffer. The issue is the extent to which
the manufacturer's literature is to be considered inviolate
and the extent to which the FDA is to be the sole arbiter
of drug dosage.
From a practical legal standpoint, it would seem that
the doctor is now "it," i.e., on the spot where there has been
a compensible drug reaction. How the package stuffer
may create liability for a physician where none existed
before is easy of illustration. For example, the package
insert for Vibramycin, a new tetracycline, a broad spectrum
antibiotic, contained the following directions for dosage:
The usual dose of Vibrarnycin (doxycycline) is 200 mg. on the
first day of treatment (administered 100 mg. every 12 hours)
followed by a maintenance dose of 100 mg./day. The mainten-
ance dose may be administered as a single dose, or as 50 mg.
every 12 hours. In the management of more severe infections
(particularly chronic infections of the urinary tract), 100 mg.
every 12 hours is recommended ... 35
As to Vibramycin, The Medical Letter, a responsible
publication, reported to its readers that:
Most Medical Letter Consultants believe that a dosage schedule
of 100 mg. once daily is inadequate and recommend 100 mg.
doses twice daily throughout the course of therapy. Because the
urinary excretion of doxycycline is slower than with other
tetracyclines, the urinary concentration of the antibiotic may be
35 1968 PHYSICIAN's DESK RivERxcn- at 943. When a new drug is
placed on the market, it is usually accompanied by an extensive promotional
campaign. Wide use of the drug may uncover additional adverse effects
which were unknown and unsuspected in the premarketing investigation.
The reasons are that: 1.) When the drug is marketed many more people
will receive it than in the testing period; and' 2.) in the investigative process,
trial dosages are usually administered to carefully-selected persons, while,
after it is marketed, it will be prescribed at random.
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too low, even with twice daily dosages, to be effective in infections
of the urinary tract.3 6
The point to be made is that it is possible that a
physician who follows the manufacturer's recommendation
in prescribing a drug may provide inadequate therapy for
his patient. But, if he deviates from the package insert,
he may be providing the basis of liability in a lawsuit
against himself.
THE DoTOR'S LIABILITY
A great hue and cry arose from the medical profession
with respect to the FDA intervention in drug prescription
and much of it seems justified. On the other hand, it is
utterly impossible today for the average medical man to
keep abreast of current literature on drugs and, even if he
could, he runs the risk of injuring his patients while
information is collated. The preferred method would seem
to be to place the burden on the manufacturer to keep the
physician informed and then to make him "it" when the
drug is prescribed. After all, the manufacturer cannot
know how sick the patient is. The manufacturer cannot
balance the hazards of leaving the disease state untreated
as against prescribing an indicated medication. While in
some instances it may be that the doctor does not have at
hand all information which might be considered desirable
in prescribing a particular drug for a particular ailment,
he does have a better opportunity than the manufacturer
to calculate the odds and to obtain more information to
make a reasonable judgment.
Again, it must be remembered that all drugs have
toxic effects as well as therapeutic benefits. Most of them
depend on their toxicity for their therapeutic action since
they act by depression of some natural metabolic process.
The difference is that the toxic proneness of the drug must
be selective to be useful. It must be capable of destroying
one form of living cell without harming another even
though the two forms of cell are in close proximity. The
ideal drug is that which is toxic to the infectious agent but
36 MEICAL LErrER, Feb. 23, 1968, at 13.
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not to the normal cells of the person to whom it is adminis-
tered. That state of perfection has not often been achieved
and so it is possible to allege that the number of cases of
adverse reactions to drugs would diminish if the drugs were
prescribed only where indicated and proper precautions
were then observed. As a doctor-lawyer has written:
It has always been the physician's responsibility to weigh risks
against benefits when administering drugs-all drugs. This has
been part of his educational foundation. Perhaps, in the past,
the test may not have been consciously applied by physicians
as often as would have been desirable; however, comprehensive
information has not always been readily available to physicians,
and it is probable the previously known risks were considered
so mild or infrequent that they seldom generated concern. Never-
theless, increased efforts to identify and to publicize drug hazards
require physicians to be more alert today to the application of
this test for every drug prescribed or administered. Failure
to do so may lead to legal as well as medical repercussions.";
Tozer (J.D.) and Kasik (M.D.) have made several
suggestions to minimize the physician's risk in drug pre-
scription." Parenthetically, it should be noted that the
suggestions also provide standards against which to judge
the doctor's conduct in potential malpractice cases.
1. It is suggested that a doctor should give pause in
prescribing a drug with which he is not thoroughly famil-
iar. The physician should be current with the literature
on adverse reactions.
2. He should know the history of his patient on
adverse reactions.
3. He must be prepared to justify the use of the drug
which he prescribes and its dangers, as opposed to other
drugs, or other methods of treatment.
4. He must be prepared to observe and follow the
signs and symptoms of adverse reactions. If laboratory
37 Mills, Physician Responsibility for Drug Prescription, 192 J.A.M.A.
460 (1965).
38 Tozer & Kasik, The Medical-Legal Aspects of Adverse Drug Reaction,
9 CLINICAL PHARMACOLOGY AND THERAI-Purics 637 (1967), a recommended
article,
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tests should be made prior to the administration of a drug,
he must make them.
5. He should consider keeping a diary of all patients
receiving drugs so that if there is a warning with respect
to a particular drug, he can pass it on to his patient.
The conclusions reached by these authors are:
None of these conclusions is easy. All of them will further
burden the already overburdened practitioner and inevitably will
place increasing demands on his time and raise the cost of care
for the patient. They may, however, have one desirable con-
sequence; they may reduce some of the enthusiasm for the use
of drugs in any and all circumstances.s9
A review of the numerous adverse reactions which are
possible following the administration of drugs is frighten-
ing. At the same time, one must be realistic, for although
drug reactions may be serious or fatal, they are not the
usual result of such therapy. The fact that three reactions
in ten million doses of penicillin may be expected to be
fatal should not be a reason for deleting the drug from the
doctor's medical arsenal. Neither does it mean, however,
that the public should be complacent about penicillin deaths
nor that the attorney should not seek to ascertain if the
legal causation was negligence.
It is a rare occurrence that a physician will be found
liable for the administration of a drug which seemed rea-
sonable in the light of foresight, although disastrous in
terms of hindsight. There are occasions where the risk in
the use of the drug would seem small as compared to the
benefit expected for the patient. There are also hyper-
sensitivities and idiosyncracies which cannot be reasonably
predicted in individual patients.
On the other hand, the patient is in no position to
judge the virtues and perils of the remedy prescribed by
his doctor. He expects relief from his ailment if for no
other reason than favorable drug propaganda. He has faith
in the ability of his doctor to heal and cure.
39 Id. at 645.
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The unalterable conclusion is that it is the physician,
and he alone, who has the responsibility for selecting the
right agent for the relief and cure of his patient's ailment.
The role of the doctor is the most important for it is on
his prescription that the drug is administered. He must
be held responsible for knowing that which is known about
the drug he prescribes.
Obviously, the plaintiffs' cases against physicians which
have the greatest potential are those in which irreversible
damage has resulted from the administration of a known
potentially toxic drug in one of five instances:
1. Where the use of the drug was contraindicated
under the circumstances.
2. Where, in any event, the indications for use were
dubious.
3. Where the ailment to be treated was misdiagnosed.
4. Where the ailment was so minor as not to require
the drug.
5. Where an improper dosage was prescribed or the
patient was given improper or inadequate instructions for
use.
There are an increasing number of gross medical errors
in administering a drug or where there has been a failure
to exercise proper precautions." Drug toxicity is all too
common where directions for use are followed to the letter
without regard to the individuality of the patient. It is
almost inevitable when such instructions are disregarded.
Drug houses and public and private research institu-
tions are advancing toward a goal of the production of
medications which will have a lower toxicity propensity.
40 E.g., Koury v. Follo, 272 N.C. 366, 158 S.E.2d 548 (1968). An
infant lost his hearing following five injections by a pediatrician of Strep-
combiotic for bronchitis. The manufacturer had marked the drug container
"Not for Pediatric Use" and the attending physician knew that Streptomycin
contained in the compound could impair the auditory nerves. The plaintiff's
expert witness testified that the dosage administered was approximately
twice the upper safe limit of dosage for an infant and five times the stand-
ard dosage for children as recommended in standard tests.
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Ultimately, the public will benefit from their research and
testing. Drugs are the chief weapon in the fight against
disease. They must be used, but with judgment and cau-
tion, and the attorney must be critical of the process. The
trial attorney in order to protect a drug-injured client must
be ever alert to the published warnings of adverse drug
reactions and to the expanding role of liability of the phy-
sician as pronounced by courts everywhere.
